A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Phase 1

Completed

• Conditions: Atopic Dermatitis
• Interventions: Drug: AK120 or placebo- Part 2- Cohort 4; Drug: AK120 or placebo- Part 1- Cohort 5; Drug: AK120 or placebo- Part 1- Cohort 1; Drug: AK120 or placebo- Part 2- Cohort 1; Drug: AK120 or placebo- Part 2- Cohort 2; Drug: AK120 or placebo- Part 1- Cohort 4; Drug: AK120 or placebo- Part 1- Cohort 2; Drug: AK120 or placebo- Part 1- Cohort 3; Drug: AK120 or placebo- Part 2- Cohort 3

• Registration Number: NCT04256174
• Lead Sponsor: Akesobio Australia Pty Ltd

Brief Summary

A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis

Detailed Description

This is a phase 1, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects (part 1, single ascending dose) and subjects with moderate- to- severe atopic dermatitis(part 2, multiple ascending dose)

Study Timeline

• Study First Submitted: 2020-02-03
• Study First Submitted QC: 2020-02-03
• Study First Posted: 2020-02-05
• Study Start: 2020-06-15
• Primary Completion: 2021-10-29
• Study Completion: 2021-10-29
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-15
• Last Update Posted: 2022-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Subjects must meet all the following inclusion criteria (as applicable) to be eligible for participation in this study:

Part 1:

1. Willing and able to understand and sign an Informed Consent Form (ICF).
2. Women or men between 18 and 55 years of age, inclusive, at screening.
3. Must have a calculated body mass index within 18.0 to 30.0 kg/m2 (inclusive) at screening, and a total body weight ≥50 kg for men or ≥45 kg for women at screening and Day -1 before randomization.
4. Women of childbearing potential who are sexually active must use one of the permitted methods of contraception from screening until at least 180 days after dosing of study medication.
5. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use an effective method of contraception from Day 1 through 180 days after dosing of study medication.
6. Must, in the opinion of the Investigator, be in good general health based upon medical history, physical examination (including vital signs), and 12-lead ECG; and clinical laboratory tests

Part 2:

1. Male or female, aged 18 to 65 years (inclusive) at time of Screening.
2. Chronic atopic dermatitis (AD) diagnosed by the revised Hanifin and Rajka criteria that has been present for at least 1 year before the Screening visit.
3. EASI score ≥12 at the screening and baseline visits.
4. IGA score ≥3 at the screening and baseline visits.
5. BSA of AD involvement ≥10% at the screening and baseline visits.
6. History of an inadequate response or medically inappropriate use of topical drug treatment, in the judgment of the Investigator, to AD treatment with a topical regimen of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors or with phototherapy within 6 months of the Screening visit.
7. Subjects must be applying stable doses of an additive-free, basic bland emollient twice daily for at least 7 days before the baseline visit.

Major

Exclusion Criteria

Subjects who meet any of the following exclusion criteria will not be enrolled in this study:

Part 1:

1. Clinically significant clinical safety laboratory result, or blood pressure or electrocardiogram (ECG) abnormalities.
2. Current acute infection or history of acute infection within 7 days prior to receipt of the study drug.
3. Have a recent history of conjunctivitis or keratitis within 6 months prior to screening.
4. History or complications of tuberculosis, or evidence of latent tuberculosis by QuantiFERON®-TB Gold screening.
5. Are positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) at screening.

Part 2:

1. The washout period for prior drug therapy (eg. corticosteroids, immunosuppressive/immunomodulating, biologics, phototherapy, Chinese medicine，anti-infective agents) is inadequate.
2. Any medical or psychiatric condition, laboratory or ECG parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.
3. History of exposure to active TB, and/or history or current evidence of TB infection; and/or Chest X-ray showed old TB lesions at Screening or within 3 months before the Screening visit ..
4. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody with positive hepatitis C virus (HCV) RNA polymerase chain reaction; positive HIV serology at screening.
5. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.
6. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Part 2: Loading dose cohort	AK120 or placebo- Part 2- Cohort 4	A loading dose followed by multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
Part 1: 600 mg cohort	AK120 or placebo- Part 1- Cohort 5	Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
Part 1:15mg cohort	AK120 or placebo- Part 1- Cohort 1	Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
Part 2: low dose cohort	AK120 or placebo- Part 2- Cohort 1	Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
Part 2: medium dose cohort	AK120 or placebo- Part 2- Cohort 2	Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
Part 1: 300 mg cohort	AK120 or placebo- Part 1- Cohort 4	Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
Part 1: 50mg cohort	AK120 or placebo- Part 1- Cohort 2	Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
Part 1: 150mg cohort	AK120 or placebo- Part 1- Cohort 3	Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
Part 2: high dose cohort	AK120 or placebo- Part 2- Cohort 3	Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.

Primary Outcome Measures

Name	Time	Method
Adverse events(AEs)/serious adverse events(SAEs)	From signing of informed consent through through 12 weeks post-dose	Incidence of treatment emergent adverse events(AEs)/serious adverse events(SAEs)

Secondary Outcome Measures

Name	Time	Method
Area under the concentration-time curve (AUC)	From baseline through 12 weeks postdose	Area under the concentration-time curve (AUC) of serum concentration of AK120
Anti-drug antibodies(ADAs)	From baseline through 12 weeks postdose	Number and percentage of subjects who develop detectable anti-drug antibodies(ADAs)
Maximum observed serum concentration (Cmax)	From baseline through 12 weeks post-dose	Maximum observed serum concentration (Cmax) of AK120
Thymus and activation regulated chemokine (TARC)/Chemokine Ligand 17(CCL17)	From baseline through 12 weeks post-dose	Change from baseline in serum levels of thymus activation and regulated chemokine (TARC)/Chemokine Ligand 17 (CCL17) in serum
Investigator global assessment (IGA) (part 2)	From baseline through 12 weeks postdose	The proportion of subjects with Investigator global assessment (IGA) 0 to 1 and subjects with IGA reduction from baseline of ≥ 2-point.; IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 6-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe；5 = very severe) based on erythema and papulation/infiltration.
Change from baseline in Eczema Area and Severity Index (EASI) score(part 2)	From baseline through 12 weeks postdose	The EASI score was used to measure the severity and extent of atopic dermatitis (AD). The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Change from baseline in body surface area (BSA) of AD involvement. (part 2)	From baseline through 12 weeks postdose	Body surface area determined by palm method where 1 palm is equivalent to 1%. Total body surface area ranges from 1% to 100%, with the higher body surface area reflecting the worse severity of AD.
Pruritus-Numeric Rating Scale (P-NRS) (part 2)	From baseline through 12 weeks postdose	The proportion of subjects with Pruritus-Numeric Rating Scale (P-NRS) improvement (reduction) from baseline of ≥ 3-point.; Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\])

Trial Locations

Locations (13)

P3 Research Tauranga; 🇳🇿 Tauranga, New Zealand

CMAX Clinical Research; 🇦🇺 Adelaide, Australia

Sinclair Dermatology; 🇦🇺 East Melbourne, Australia

P3 Research Wellington; 🇳🇿 Wellington, New Zealand

Christchurch Clinical Studies Trust; 🇳🇿 Christchurch, New Zealand

Southern Clinical Trials - Christchurch; 🇳🇿 Christchurch, New Zealand

Emeritus Sydney; 🇦🇺 Botany, New South Wales, Australia

Peninsula Specialist Centre; 🇦🇺 Kippa-Ring, Australia

Scientia Clinical Research Ltd; 🇦🇺 Randwick, Australia

Optimal Clinical Trials; 🇳🇿 Auckland, New Zealand

P3 Research Hawkes Bay; 🇳🇿 Havelock North, New Zealand

Southern Clinical Trials - Waitemata; 🇳🇿 Birkenhead, Auckland, New Zealand

Emeritus Melbourne; 🇦🇺 Camberwell, Victoria, Australia